I worked in his lab all summers and was also able to do research during the school year. He later moved to California and I was able to work directly with Dr Astwood. So, the summer after my first year in medical school I worked in an endocrine lab for my advisor Bill Vanderlaan.
And he was also the editor of Endocrinology, the major endocrine journal at that time. He had discovered anti-thyroid drugs that were used to treat hyperthyroidism. Ted was a professor of medicine and very famous endocrinologist. My advisor was a clinician but also had some space in a lab that was headed by Dr Ted Astwood. In my first year of medical school, I talked to my advisor and told him that I wanted to do something related to medicine as a summer job and asked him if he could give me some advice. I went to the Tufts College and majored in biology, and then to Tufts Medical School. At that time, being a doctor was a good career track for kids who were good at science, so I thought I probably would become a physician. When I was a kid, I was very good in science. Could you please briefly talk about your past experience, what made you decide to become a physician and then a scientist, and what your experience was like at the LMB of the NIH?ĭr Pastan: I was born in Winthrop Massachusetts. Interviewers: We understand that you are the founder of the LMB in the National Cancer Institute, and you are also the expert of immunotoxin therapies. For the third part, we will seek your suggestions on our society, especially on our society’s peer-reviewed journal Antibody Therapeutics. For the second part, we hope to have your insights on the challenges and opportunities of immunotoxin-based immunotherapy.
The first part centers on your background, research and your current role in the NIH. Interviewers: Today’s interview will include three parts. We feel much honored to have you as our first expert in this program. As part of this program, we plan to interview renowned experts in the therapeutic antibody field, and we will publish the interview transcripts on the Society’s website and social media channels. This interview is part of our new program experts’ perspective.
HTTPS MYTIME SCRIPPS ORG LOGIN SERIES
Interviewers: We had many successful events in the past, including our annual conference, webinar series and PharmaConnect. The mission of Chinese Antibody Society is to bring together industry leaders, healthcare providers, researchers, academics, and investors to connect and collaborate on the discovery, development, manufacturing and marketing of therapeutic antibodies. Our society is a non-profit organization, established in 2017 and serves as a platform fostering communication and collaboration among its members worldwide. Before the interview, we would like to briefly introduce our society. Cong and I are both volunteers for the Chinese Antibody Society. Thank you so much for agreeing to do an interview with us. Interviewers: This is Peng Lin and Cong Yao from the Chinese Antibody Society. Below is the transcript of the interview with Dr Pastan by the Society’s volunteers Peng Lin, PhD, JD and Cong Yao, PhD., JD.
In 2018, shortly after the Lumoxiti was approved by FDA for marketing, the Chinese Antibody Society (“the Society”) was honored to interview Dr Pastan who shared his insights on the opportunities and challenges for immunotoxin-based cancer therapy, his past experience to be a physician and then a scientist and his valuable suggestions for the Society and the Society’s peer-reviewed journal, Antibody Therapeutics. This US Food and Drug Administration (FDA)-approved drug, Lumoxiti for the treatment of patients with relapsed or refractory hairy cell leukemia (HCL), is the result of decades of research led by Dr Pastan at the National Cancer Institute at National Institutes of Health (NIH). Heyman Service to America Medal (Sammies) finalists, Ira Pastan, MD, Co-Chief of the Laboratory of Molecular Biology (LMB), discovered a new class of drugs that can successfully treat a rare form of leukemia and hold promise to be effective therapies for pancreatic and lung cancer as well as mesothelioma. Volcker Career Achievement Medal, 2020 and one of Samuel J. As a new class of anti-cancer drug, the immunotoxins have demonstrated clinical benefits for patients with cancers.Īs an honoree of Paul A. Statement of Significance: The FDA-approved Lumoxiti, a first-in-class medicine for hairy cell leukemia, is based on a remarkable translational research led by Dr Ira Pastan, a pioneer in immunotoxins.
0 kommentar(er)
